The new third-generation quinolones may be the solution to the problem of increasing bacterial resistance in respiratory tract infections (RTIs). These agents, which include sparfloxacin, grepafloxacin and levofloxacin, appear to be at least as effective as the most recent macrolides in the treatment of RTIs, according to presentations at the 20th International Congress on Chemotherapy [Sydney, Australia; July 1997].